Biomarkers and potential therapeutic targets driving progression of non-alcoholic steatohepatitis to hepatocellular carcinoma predicted through transcriptomic analysis

Biomarkers and potential therapeutic targets driving progression of non-alcoholic steatohepatitis to hepatocellular carcinoma predicted through transcriptomic analysis

BackgroundNon-alcoholic steatohepatitis (NASH) is the most prevalent chronic liver condition globally, with potential progression to cirrhosis, and even hepatocellular carcinoma (HCC). The increasing prevalence of NASH underscores the urgent need for advanced diagnostic and therapeutic strategies. D...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hui Fan, Rong Wang, Bin Wen, Jing Xiong
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-12-01
Series:	Frontiers in Immunology
Subjects:	non-alcoholic steatohepatitis triggering receptor expressed on myeloid cells 2 Annexin A2 growth/differentiation factor-15 tetratricopeptide repeat domain 39A hepatocellular carcinoma
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1502263/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Application of ursodeoxycholic acid at non-alcoholic and alcohol-induced steatohepatitis
by: Ye. A. Fedos’ina, et al.
Published: (2010-06-01)

Comprehensive treatment of patients with type 2 diabetes, complicated by diabetic kidney disease, with concomitant non-alcoholic steatohepatitis
by: Z.Ya. Kotsiubiichuk, et al.
Published: (2025-04-01)

Hepatocentric approach to achieving compensation of diabetes mellitus in people with non-alcoholic steatohepatitis
by: N.M. Protas, et al.
Published: (2024-09-01)

CAT and CXCL8 are crucial cofactors for the progression of nonalcoholic steatohepatitis to hepatocellular carcinoma, the immune infiltration and prognosis of hepatocellular carcinoma
by: Liang Yang, et al.
Published: (2025-03-01)

SMYD2 inhibitors have no effect in improving non-alcoholic steatohepatitis in mice
by: Lanzexin Yang, et al.
Published: (2025-06-01)

Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis
by: D. V. Garbuzenko
Published: (2022-01-01)

Changes in direct markers of liver fibrosis in patients with steatohepatitis non-alcoholic and alcoholic origin on the background of obesity and pathology of the biliary tract
by: A. Yu. Filippova
Published: (2017-04-01)

Correction of the clinical course of non-alcoholic steatohepatitis and diabetic kidney disease in patients with type 2 diabetes
by: Z.Ya. Kotsiubiichuk, et al.
Published: (2024-10-01)

Deposition features of heterovalent iron (Fe2 + and Fe3 +) in the liver in alcoholic and nonalcoholic steatohepatitis
by: V. A. Tumanskiy, et al.
Published: (2015-12-01)

Clinical Utility of IFIT Proteins in Human Malignancies
by: Armen Parsyan, et al.
Published: (2025-06-01)

Ductular reaction in alcoholic steatohepatitis, nonalcoholic steatohepatitis and hepatitis C virus infection (immunohistochemical study)
by: O. M. Gavrilyuk
Published: (2014-04-01)

Annexin A2: the missing piece in the puzzle of pathogen-induced damage
by: Chao Li, et al.
Published: (2023-12-01)

Quantitative longitudinal investigation of non-alcoholic steatohepatitis in mice by photoacoustic microscopy
by: Jianshuang Wei, et al.
Published: (2025-08-01)

Annexin A2: the feasibility of being a therapeutic target associated with cancer metastasis and drug resistance in cancer microenvironment
by: Song Weijie
Published: (2024-12-01)

Aloperin improves liver non-alcoholic steatohepatitis in vitro and in vivo
by: Zhongsheng Guo, et al.
Published: (2020-05-01)

Molecular characterisation and expression analysis of an interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) homologue from Asian seabass (Lates calcarifer)
by: Krishnapriya Raji Sathyan, et al.
Published: (2024-12-01)

Steatohepatitis in Children with Obesity
by: Alexander A. Zvyagin, et al.
Published: (2021-08-01)

SENSITIVITY AND SPECIFICITY OF VECTORCARDIOGRAPHY IN DIAGNOSTICS OF ACUTE MYOCARDIAL INFARCTION COMORBID WITH LIVER STEATOSIS AND NON-ALCOHOLIC STEATOHEPATITIS
by: I. E. Belaya, et al.
Published: (2015-12-01)

Identification of biomarkers between coronary artery disease and non-alcoholic steatohepatitis: a combination of bioinformatics and machine learning
by: Yihong Lin, et al.
Published: (2025-07-01)

1,25-dihydroxyvitamin D3 improves non-alcoholic steatohepatitis phenotype in a diet-induced rat model
by: Mei Liu, et al.
Published: (2025-03-01)

Immune and Inflammatory Pathways in Non-Alcoholic Steatohepatitis (NASH). An update
by: Sorina Cezara Coste, et al.
Published: (2019-05-01)

Minimal Hepatic Encephalopathy in Patients with Alcohol Related and Non-alcoholic Steatohepatitis Related Cirrhosis by Psychometric Hepatic Cephalopathy Score and Critical Flicker Frequency
by: Nitin Jagtap, et al.
Published: (2021-03-01)

Genetic aspects of non-alcoholic fatty liver disease development
by: V. A. Akhmedov, et al.
Published: (2021-06-01)

Experimental murine non-alcoholic steatohepatitis is associated with behavioural, cognitive, and peripheral neuronal dysfunction
by: V. A. Prikhodko, et al.
Published: (2025-03-01)

NON-ALCOHOLIC FATTY LIVER DISEASE OUTCOMES FUNNEL
by: D. V. Blinov
Published: (2015-12-01)

Sulforaphane ameliorates non-alcoholic steatohepatitis by KLF4-mediated macrophage M2 polarization
by: Xianghui Huang, et al.
Published: (2024-09-01)

Mesenteric panniculitis associated with non-alcoholic fatty liver disease: a case series
by: Mehreen Siyal, et al.
Published: (2024-04-01)

Corrigendum: Editorial: Mechanistic insight and therapeutic potential for the management of non-alcoholic steatohepatitis (NASH)
by: Umashanker Navik, et al.
Published: (2024-12-01)

Changes in rat liver fatty acid profile in experimental non-alcoholic steatohepatitis
by: E. B. Shustov, et al.
Published: (2021-12-01)

Exosomal novel-miRNA-126 mediates vascular endothelial dysfunction by targeting AhR-NLRP3 pathway in nonalcoholic steatohepatitis
by: Qiuhe Chen, et al.
Published: (2025-03-01)

NFE2L2 and SLC25A39 drive cuproptosis resistance through GSH metabolism
by: Jiao Liu, et al.
Published: (2024-11-01)

The state of the cytokine profile in pregnant women with non-alcoholic fatty liver disease at the stage of non-alcoholic steatohepatitis with varying degrees of comorbid obesity under the influence of the developed complex therapy program
by: L. V. Bahnii, et al.
Published: (2023-04-01)

TREM2 in MASH: integrating lipid metabolism and immune response
by: Shuyi Shi, et al.
Published: (2025-06-01)

Clinical characteristics of patients with hepatic steatosis and non-alcoholic steatohepatitis combined with obesity and disorders of the biliary tract, depending on the body mass index.
by: A. Yu. Filippova
Published: (2016-03-01)

PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN REPUBLIC OF BASHKORTOSTAN (REGIONAL RESULTS OF DIREG 2 STUDY)
by: D. Kh. Kalimullina, et al.
Published: (2017-03-01)

Knockdown of annexin A2 enhances the host cell apoptosis induced by Eimeria tenella
by: Jixia Wang, et al.
Published: (2025-07-01)

l-[5-11C]Glutamine PET imaging noninvasively tracks dynamic responses of glutaminolysis in non-alcoholic steatohepatitis
by: Yiding Zhang, et al.
Published: (2025-02-01)

Hepatocellular Carcinoma: Aetiology and Mechanisms of Development. A Literature Review
by: K. V. Menshikov, et al.
Published: (2022-07-01)

High intake of n-6 polyunsaturated fatty acid exacerbates non-alcoholic steatohepatitis by the involvement of multiple metabolic pathways
by: Jian-Tong, et al.
Published: (2025-06-01)

Exosomal ANXA2 facilitates ovarian cancer peritoneal metastasis by activating peritoneal mesothelial cells through binding with TLR2
by: Jingni Zhang, et al.
Published: (2024-12-01)